{'fraction_non_alphanumeric': 0.08216292134831461, 'fraction_numerical': 0.07654494382022473, 'mean_word_length': 4.418250950570342, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus

Prevalence of GBV‐C/HGV was determined in a cohort of HIV‐infected patients, via a reverse transcription–polymerase chain reaction detection of RNA in serum, amplifying the NS5 region of GBV‐C/HGV genome. GBV‐C/HGV RNA was detected in 143 (37.7%) of 379 patients, with similar results in the different HIV risk groups: 25/56 (44.6%) in intravenous drug users, 66/161 (41%) in homo‐ and bisexual men, 35/108 (32.4%) in heterosexual patients, 6/20 (30%) in transfusion recipients (P = 0.41). There was no difference according to the presence or absence of hepatitis C virus infection. In univariate analysis, GBV‐C/HGV genome prevalence was lower in patients over 50 years old (18.2%), compared to other age groups (20–29 years: 34.2%; 30–39 years: 44.3%; 40–49 years: 36.7%, P = 0.03), as well as in patients with normal CD4 cell count (29.2% vs. 45.4% between 200–500/mm3, and 35.3% below 200 CD4/mm3, P = 0.012) and individuals with a chronic hepatitis B. However, in the multivariate analysis, the only prognostic factor of GBV‐C/HGV RNA positivity was the presence of a chronic hepatitis B, compared to the absence of any HBV marker, or a previous exposition to HBV (presence of anti‐HBc and/or anti‐HBs, absence of HBsAg), or the presence of anti‐HBs alone. J. Med. Virol. 57:75–79, 1999. © 1999 Wiley‐Liss, Inc.